Open an Account
search icon
4
NOTIFICATIONS
Best Algo trading app in India
Bigul

GLENMARK PHARMACEUTICALS LTD. - 532296 - Board Meeting Outcome for Outcome Of The Board Meeting Held On 7Th April, 2022

 Pursuant to Regulation 30 of the SEBI LODR, Regulations 2015, we wish to inform you that, based on the recommendation of the Nomination and Remuneration Committee, Board at its meeting held today, has approved the following: a) Re-appointment of Mr. Glenn Saldanha (DIN- 00050607) as Chairman & Managing Director of the Company for a further period of 5 years with effect from 16th May, 2022; and b) Re-appointment of Mrs. Cherylann Pinto (DIN- 00111844) as an Executive Director - Corporate Services of the Company for a further period of 5 years with effect from 16th May, 2022
07-04-2022
Bigul

GLENMARK PHARMACEUTICALS LTD. - 532296 - Compliance Certificate Under Regulation 7(3) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Financial Year Ended 31St March, 2022

 This is to certify that all activities in relation to both physical and electronic share transfer facilities are maintained by Registrar to an issue and Share Transfer Agent 'M/s. KFin Technologies Limited' registered with Securities Exchange Board of India under Registration Number INR000000221.
05-04-2022
Bigul

GLENMARK PHARMACEUTICALS LTD. - 532296 - Intimation Of Operations Committee Meeting To Authorize The Repurchase Of Outstanding U.S.$200,000,000 2.00 Per Cent. Resettable Onward Starting Equity-Linked Securities Due 2022 ('Bonds') By Glenmark Pharmaceuticals Limited (The Company') And Issuance Of The Notice Of Early Redemption By The Company To The Holders Of The Bonds.

 Operations Committee Meeting to authorize the repurchase of outstanding U.S.$200,000,000 2.00 per cent. Resettable Onward Starting Equity-linked Securities Due 2022 ("Bonds") by Glenmark Pharmaceuticals Limited (the "Company") and issuance of the Notice of Early Redemption by the Company to the holders of the Bonds.
04-04-2022
Bigul

GLENMARK PHARMACEUTICALS LTD. - 532296 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

 Pursuant to Regulation 39(3) and other applicable regulations of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and in terms of SEBI Circular No. SEBI/HO/MIRSD/MIRSD_RTAMB/P/CIR/2022/8 dated 25th January, 2022, we hereby inform you that the Registrar and Transfer Agent of the Company, M/s. KFin Technologies Limited has issued a ''Letter of Confirmation'' to shareholder in lieu of certificates reported as lost by them.
01-04-2022

Glenmark Pharma receives US FDA approval for lacosamide tablets to treat seizure

 Lacosamide tablets will be available in 50 mg, 100 mg, 150 mg and 200 mg respectively and the pharma giant plans to launch the product immediately in the US market.
21-03-2022
Bigul

GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

 Glenmark Pharmaceuticals receives ANDA approval for Lacosamide Tablets USP, 50 mg, 100 mg, 150 mg and 200 mg
21-03-2022
Bigul

GLENMARK PHARMACEUTICALS LTD. - 532296 - Intimation Of Change Of Name Of The Registrar And Share Transfer Agent Of The Company From "Kfin Technologies Private Limited" To "Kfin Technologies Limited"

 We have been informed by the Registrar and Share Transfer Agent ("RTA") of the Company through email that pursuant to conversion of its status from private limited company to public limited company, its name has been changed from "KFin Technologies Private Limited" to "KFin Technologies Limited". We request you to take note of the above and update in your records, name of the RTA of the Company as "KFin Technologies Limited".
15-03-2022
Bigul

GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

 Glenmark inks agreement with Astrazeneca to commercialize its product Pulmicort Respules(r) in Columbia
14-02-2022
Bigul

Q3FY22 Quarterly Result Announced for Glenmark Pharmaceuticals Ltd.

 Glenmark Pharmaceuticals declares Q3FY22 result: Glenmark Pharma reports revenue growth of 13.9% and EBITDA growth of 30.8% YoY for Q3 FY 2021-22 India Business grew by 14.2% to Rs. 10,069 Mn. ROW Business grew by 24.3% to Rs. 4,178 Mn. Europe Business grew by 21.5% to Rs. 3,807 Mn. EBITDA of Rs. 6,932 Mn grew by 30.8% YoY, with margins of 21.8%. For the third quarter of FY 2021-22, Glenmark’s consolidated revenue was at Rs. 31,734 Mn as against Rs. 27,868 Mn recording an increase of 13.9% YoY. Consolidated EBITDA was at Rs. 6,932 Mn in the quarter ended December 31, 2021 as against Rs. 5,301 Mn in the previous corresponding quarter, registering an increase of 30.8% YoY. “We had a landmark quarter with strong performance and the achievement of some key milestones. We closed our eighth out-licensing deal in our innovation pipeline, establishing us as one of the leading innovation-driven pharma companies in the country. Our businesses have also maintained their good growth momentum.” said Glenn Saldanha, Chairman & Managing Director, Glenmark Pharmaceuticals Ltd. He further added, “We are on track to achieve our key business objectives for the financial year.” Result PDF
14-02-2022
Bigul

GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

 Details of Earnings Call slated for Monday, February 14, 2022 at 8:30 a.m. - 9:30 a.m. (IST)
13-02-2022
Next Page
Close

Let's Open Free Demat Account